Summary
Global Markets Direct’s, ‘RaQualia Pharma Inc. - Product Pipeline Review - 2016’, provides an overview of the RaQualia Pharma Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by RaQualia Pharma Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of RaQualia Pharma Inc.
- The report provides overview of RaQualia Pharma Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses RaQualia Pharma Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features RaQualia Pharma Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate RaQualia Pharma Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for RaQualia Pharma Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RaQualia Pharma Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
RaQualia Pharma Inc. Snapshot 5
RaQualia Pharma Inc. Overview 5
Key Information 5
Key Facts 5
RaQualia Pharma Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
RaQualia Pharma Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
RaQualia Pharma Inc. - Pipeline Products Glance 11
RaQualia Pharma Inc. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
RaQualia Pharma Inc. - Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
RaQualia Pharma Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
RaQualia Pharma Inc. - Drug Profiles 15
tegoprazan 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
RQ-00000010 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
RQ-00310941 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
RQ-00000774 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
RQ-00201894 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
RQ-00202730 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
RQ-00203066 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
RQ-00203078 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
RQ-00433412 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule to Block Cav3.2 for Neuropathic Pain 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecules to Block Nav1.7 Sodium Channel for Pain 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecules to Block Nav1.8 Sodium Channel for Pain 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RQ-00434739 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule for Pain 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule for Undisclosed Indication 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
RaQualia Pharma Inc. - Pipeline Analysis 30
RaQualia Pharma Inc. - Pipeline Products by Target 30
RaQualia Pharma Inc. - Pipeline Products by Route of Administration 32
RaQualia Pharma Inc. - Pipeline Products by Molecule Type 33
RaQualia Pharma Inc. - Pipeline Products by Mechanism of Action 34
RaQualia Pharma Inc. - Recent Pipeline Updates 36
RaQualia Pharma Inc. - Dormant Projects 40
RaQualia Pharma Inc. - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43
List of Tables
RaQualia Pharma Inc., Key Information 5
RaQualia Pharma Inc., Key Facts 5
RaQualia Pharma Inc. - Pipeline by Indication, 2016 8
RaQualia Pharma Inc. - Pipeline by Stage of Development, 2016 9
RaQualia Pharma Inc. - Monotherapy Products in Pipeline, 2016 10
RaQualia Pharma Inc. - Phase III, 2016 11
RaQualia Pharma Inc. - Phase I, 2016 12
RaQualia Pharma Inc. - Preclinical, 2016 13
RaQualia Pharma Inc. - Discovery, 2016 14
RaQualia Pharma Inc. - Pipeline by Target, 2016 31
RaQualia Pharma Inc. - Pipeline by Route of Administration, 2016 32
RaQualia Pharma Inc. - Pipeline by Molecule Type, 2016 33
RaQualia Pharma Inc. - Pipeline Products by Mechanism of Action, 2016 35
RaQualia Pharma Inc. - Recent Pipeline Updates, 2016 36
RaQualia Pharma Inc. - Dormant Developmental Projects,2016 40
RaQualia Pharma Inc., Other Locations 41
RaQualia Pharma Inc., Subsidiaries 41
List of Figures
RaQualia Pharma Inc. - Pipeline by Top 10 Indication, 2016 7
RaQualia Pharma Inc. - Pipeline by Stage of Development, 2016 9
RaQualia Pharma Inc. - Monotherapy Products in Pipeline, 2016 10
RaQualia Pharma Inc. - Pipeline by Top 10 Target, 2016 30
RaQualia Pharma Inc. - Pipeline by Route of Administration, 2016 32
RaQualia Pharma Inc. - Pipeline by Molecule Type, 2016 33
RaQualia Pharma Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 34
